Anticipating full benefits from the new papillomavirus vaccines

Reviews in Medical Virology

Volumn 17, Issue 1, 2007, Pages 1-3

  Griffiths, P D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE TRANSMISSION; EDITORIAL; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNIZATION; INFECTION RISK; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CANCER; VERRUCA VULGARIS;

CLINICAL TRIALS; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INCIDENCE; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; WORLD HEALTH;

EID: 33846316764     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.528     Document Type: Editorial

References (27)

1. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347(21): 1645-1651.
2. Pagliusi SR, Teresa AM. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004; 23(5): 569-578.
3. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364(9447): 1757-1765.
4. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367(9518): 1247-1255.
5. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6(5): 271-278.
6. Stanley MA. Human papillomavirus vaccines. Rev Med Virol 2006; 16(3): 139-149.
7. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69(6): 3959-3963.
8. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995; 92(25): 11553-11557.
9. Carter JJ, Wipf GC, Madeleine MM, Schwartz SM, Koutsky LA, Galloway DA. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol 2006; 80(10): 4664-4672.
10. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338(7): 423-428.
11. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006; 354(25): 2645-2654.
12. Burchell AN, Richardson H, Mahmud SM, et al. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol 2006; 163(6): 534-543.
13. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006; 3(5): e138.
14. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006; 24(Suppl. 3): S26-S34.
15. Munoz N, Bosch FX, de SS, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348(6): 518-527.
16. Hebner CM, Laimins LA. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 2006; 16(2): 83-97.
17. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006; 24(Suppl. 3): S11-S25.
18. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992; 89(24): 12180-12184.
19. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 1993; 67(1): 315-322.
20. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24(33-34): 5937-5949.
21. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364(9430): 249-256.
22. Kitchener HC, Almonte M, Wheeler P, et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 2006; 95(1): 56-61.
23. NHS Cervical Screening Programme. Who is eligible for cervical screening? 2005. http: www.cancerscreening.nhs.uk/cervical/index.html#eligible.
24. Franco EL, Cuzick J, Hildesheim A, de SS. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006; 24(Suppl. 3): S171-S177.
25. Crombie IK, Orbell S, Johnston G, Robertson AJ, Kenicer M. Women's experiences at cervical screening. Scott Med J 1995; 40(3): 81-82.
26. Lerman C, Miller SM, Scarborough R, Hanjani P, Nolte S, Smith D. Adverse psychologic consequences of positive cytologic cervical screening. Am J Obstet Gynecol 1991; 165(3): 658-662.
27. Brown RE, Breugelmans JG, Theodoratou D, Benard S. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006; 22(4): 663-670.